Methadone, buprenorphine, and street drug interactions with antiretroviral medications

Current HIV/AIDS Reports

Volumn 7, Issue 3, 2010, Pages 152-160

  Gruber, Valerie A ^a   McCance Katz, Elinore F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti HIV agents; Buprenorphine; Drug interactions; Methadone; Street drugs

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 HYDROXYBUTYRIC ACID; ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; BENZODIAZEPINE DERIVATIVE; BUPRENORPHINE; CANNABIS; COCAINE; DARUNAVIR PLUS RITONAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; HYDROCODONE; INDINAVIR PLUS RITONAVIR; LOPINAVIR PLUS RITONAVIR; METHADONE; NELFINAVIR; NEVIRAPINE; OXYCODONE; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; RITONAVIR PLUS TIPRANAVIR; SAQUINAVIR; STREET DRUG; UNINDEXED DRUG; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NARCOTIC ANALGESIC AGENT;

AREA UNDER THE CURVE; CONFUSION; CONSTIPATION; DIZZINESS; DRUG ABSORPTION; DRUG ABUSE; DRUG ANTAGONISM; DRUG CLEARANCE; DRUG DEPENDENCE; DRUG DISPOSITION; DRUG DOSE INCREASE; DRUG EXCRETION; DRUG IMPURITY; DRUG METABOLISM; DRUG POTENTIATION; GLUCURONIDATION; HEART ARRHYTHMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; MENTAL HEALTH; OPIATE ADDICTION; PAIN; PARANOIA; RESPIRATION DEPRESSION; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; WITHDRAWAL SYNDROME; COMPLICATION; DRUG INTERACTION; HIV INFECTIONS; OPIOID-RELATED DISORDERS;

ANALGESICS, OPIOID; ANTI-HIV AGENTS; BUPRENORPHINE; DRUG INTERACTIONS; HIV INFECTIONS; HUMANS; METHADONE; OPIOID-RELATED DISORDERS; RITONAVIR; STREET DRUGS;

EID: 77955985534     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-010-0048-2     Document Type: Review

References (50)

1. Center for Disease Control and Prevention (CDC): HIV and AIDS in the United States: a picture of today's epidemic. Available at http://www.cdc.gov/ hiv/topics/surveillance/united-states.htm.Accessed January 26, 2009.
2. Cook JA, Burke-Miller JK, Cohen MH, et al.: 2008: Crack cocaine, disease progression, and mortality in a multicenter cohort of HIV-1 positive women. AIDS 2008, 22:1355-1363.
3. Hser Y, Hoffman V, Grella CE, Anglin D: A 33-year follow-up of narcotics addicts. Arch Gen Psychiatry 2001, 58:503-508.
4. Department of Health and Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at http://www.aidsinfo.nih.giv/ContentFiles/AdultandAdolescentGL.pdf. Accessed March 5, 2010.
5. Wynn GH, Cozza KL, Zapor MJ, et al.: Med-psych drug-drug interactions update: Antiretrovirals, Part III: Antiretrovirals and drugs of abuse. Psychosomatics 2005, 46:79-87.
6. Chiappelli F, Frost P, Manfrini E, et al.: Cocaine blunts human CD4+ cell activation. Immunopharmacology 1994, 28:233-240.
7. Pellinen P, Stenbäck F, Kojo A, et al.: Regenerative changes in hepatic morphology and enhanced expression of CYP2B10 and CYP3A during daily administration of cocaine. Hepatology 1996,23:515-523.
8. Lopez P, Velez R, Rivera V: Characteristics of P-glycoprotein (Pgp) upregulated in chronic cocaine users and HIV infectedpersons. Retrovirology 2005, 2(Suppl 1):142.
9. Shaik N, Giri N, Pan G, Elmquist WF: P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution. Drug Metab Dispos 2007, 35:2076-2085.
10. Bramuglia GF, Cortata CM, Curras V, et al.: Relationship between p-glycoprotein activity measured in peripheral blood mononuclear cells and indinavir bioavailability in healthy volunteers. J Pharm Sci 2009, 98:327-336.
11. Henry JA, Hill IR: Fatal interaction between ritonavir and MDMA. Lancet 1998, 352:1751-1752.
12. Harrington RD, Woodward JA, Hooton TM, Horn JR: Lifethreatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate. Arch Intern Med 1999, 159:2221-2224.
13. Greenblatt DJ, von Moltke LL, Harmatz JS, et al.: Alprazolamritonavir interaction: Implications for product labeling. Clin Pharmacol Ther 2000, 67:335-341.
14. Kosel BW, Aweeka FT, Benowitz NL, et al.: The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS 2002, 16:534-550.
15. Abrams DI, Hilton JF, Leiser RJ, et al.: Short-term effects of cannabinoids in patients with HIV-1 infection: A randomized,placebo-controlled clinical trial. Ann Intern Med 2003, 139:258-266.
16. Arnsten JH, Demas PA, Grant RW, et al.: Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med 2002, 17:377-381.
17. Center for Substance Abuse Treatment: Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs. Treatment Improvement Protocol (TIP) Series 43. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2005.
18. McCance-Katz EF: Office based treatment of opioid dependence with buprenorphine. Harv Rev Psychiatry 2004, 12:321-338.
19. Gerber JG, Rhodes RJ, Gal J: Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality 2004, 16:36-44.
20. Kharasch ED, Walker A, Whittington D, et al.: Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity. Drug Alcohol Depend 2009, 101:158-168. In healthy volunteers, the PI nelfinavir increased renal clearance of methadone, resulting in 40% decrease in methadone plasma concentrations even though nelfinavir also inhibited CYP3A4 by 50%.
21. Kharasch ED, Hoffer C, Whittington D, et al.: Methadone pharmacokinetics are independent of cytochrome P4503A(CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir. Anesthesiology 2009, 110:660-672. In healthy volunteers, indinavir/ritonavir had no significant effects on methadone plasma concentrations, clearance, or bioavailability.
22. Cone E, Gorodetzky C, Yousefnejad D, et al.: The metabolism and excretion of buprenorphine in humans. Drug Metab Dispos 1984, 12:577-581.
23. Walsh SL, Preston KL, Stitzer ML, et al.: Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994, 55:569-580.
24. McCance-Katz EF, Gourevitch MN, Arnsten J, et al.: Modified directly observed therapy (MDOT) for injection drug users with HIV disease. Am J Addictions 2002, 11:271-278. Directly observed ARV administration can be used as a means of improving outcomes in methadone-maintained patients with HIV with histories of nonadherence. Efavirenz is associated with major decreases in methadone plasma concentrations frequently leading to need for dose increases of approximately 50%.
25. Arroyo E, Valenzuela B, Portilla J, et al.: Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily. Eur J Clin Pharmacol 2007, 63:669-675. Ten HIV-positive patients on stable methadonetherapy were started on the NNRTI nevirapine, a CYP3A4 inducer. After 7 days, the methadone AUC was reduced by 63%, resulting in opioid withdrawal symptoms in 9 of 10 patients, and requiring an average methadone dose increase of 20%. Increasing the nevirapine dose from 200 to 400 mg daily did not further decrease the methadone AUC.
26. Scholler-Gyure M, van den Brink W, Kakuda TN, et al.: Pharmacokinetic and pharmacodynamic study of the concomitant administration of methadone and TMC125 in HIV-negative volunteers. J Clin Pharmacol 2008, 48:322-329. Sixteen HIV-negative methadone maintenance patients received etravirine, a CYP3A4 inducer and CYP2C19 inhibitor, for 14 days. Methadone AUC increased slightly without adverse events. Although no opioid withdrawal symptoms were observed during the 14-day study, they may occur later after CYP2C19 induction takes effect. This study was conducted by Tibotec, the pharmaceutical company that developed etravirine.
27. Sekar V, El Malt M, De Paepe M, et al.: Pharmacokinetic interaction between darunavir, a new protease inhibitor, and methadone. Presented at the 8th International Congress on Drug Therapy in HIV Infection. Glasgow, UK; November 12-16, 2006.Available at www.natap.org/2006/Glasgow/Glasgow-53.htm.Accessed March 5, 2010.
28. McCance-Katz EF, Rainey P, Friedland G, Jatlow P: The protease inhibitor lopinavir/ritonavir may produce opiate withdrawal in methadone-maintained patients. Clin Infect Dis 2003, 37:476-482.Withdrawal was documented in methadone-maintained participants receiving standard clinical doses of lopinavir/ritonavir.
29. Lüthi B, Huttner A, Speck RF, Mueller NJ: Methadone-induced Torsade de pointes after stopping lopinavir-ritonavir. Eur J Clin Microbiol Infect Dis 2007, 26:367-369. This case report describes how after the methadone dose was increased to compensate for induction of methadone metabolism by lopinavir/ ritonavir, when the opinavir/ritonavir was stopped the patient had a cardiac arrhythmia due to excessive methadone levels.
30. McCance-Katz EF, Rainey PM, Smith P, et al.: Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and nelfinavir. Am J Addict 2004, 13:163-180. This study showed that despite substantial and significant decreases in methadone plasma concentrations, withdrawal did not occur, underscoring the need to monitor patients individually for adverse drug-drug interactions even when a drug interaction might be expected.
31. Kharasch ED, Bedynek PS, Park S, et al.: Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics:I. Evidence against CYP3A mediation of methadone clearance. Clin Pharmacol Ther 2008, 84:497-505. In healthy volunteers, the PI ritonavir immediately increased renal clearance of methadone 40% to 50%, resulting in decreased methadone plasma concentrations even though ritonavir also inhibited CYP3A4 by 70%.
32. Tipranavir/ritonavir Product Label. http://www.accessdata.fda.gov/ scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDrug Details Accessed March 5, 2010.
33. Dumond JB, Vourvahis M, Rezk NL, et al.: A phenotypegenotypeapproach to predicting CYP450 and p-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin Pharmacol Ther 2010 February 10 (Epub ahead of print). This study showed that in addition to its known inhibition of CYP3A and 2D6, tipranavir/ritonavir induced CYP2C19 (which is known to metabolize methadone) and intestinal p-glycoprotein.
34. Friedland G, Andews L, Schreibman T, et al.: Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. AIDS 2005, 19:1635-1641.
35. Jamois C, Smith P, Morrison R, et al.: Effect of saquinavir/ ritonavir (1000/100 mg bid) on the pharmacokinetics of methadone in opiate dependent HIV-negative patients on stable methadone therapy. Addict Biol 2009, 14:321-327. Thirteen HIVnegative methadone maintenance patients received saquinavir/ ritonavir for 14 days. R-methadone AUC decreased only slightly (19%), and no opioid withdrawal or excess was observed.
36. Cao YJ, Smith PF, Wire MB, et al.: Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects. Pharmacotherapy 2008, 28:863-874. Twenty-six HIV-negative methadone maintenance patients received fosamprenavir-ritonavir for 14 days. This reduced R-methadone AUC only slightly (18%), and no opioid withdrawal or excess was observed.
37. McCance-Katz EF, Moody DE, Morse G, et al.: Interactions between buprenorphine and antiretrovirals I: Non-nucleoside reverse transcriptase inhibitors I: efavirenz and delavirdine. Clin Infect Dis 2006, 43(Suppl 4):S224-S234. Twenty HIV-negative patients on buprenorphine maintenance received delavirdine for 7 days or efavirenz for 15 days. Delavirdine increased and efavirenz decreased buprenorphine AUC, but no opioid withdrawal or adverse symptoms were observed. Buprenorphine did not alter antiretroviral pharmacokinetics.
38. McCance-Katz EF, Moody DE, Morse E, et al.: Lack of clinically significant drug interactions between nevirapine and buprenorphine. Am J Addict 2010, 19:30-37. Seven HIV-negative patients on buprenorphine maintenance received nevirapine for 15 days. Buprenorphine AUC decreased only slightly, and no opioid withdrawal symptoms or excess were observed. Nevirapine levels were also not significantly lower than among HIV-positive control subjects receiving nevirapine and not buprenorphine.
39. McCance-Katz EF, Moody DE, Morse G, et al.: Interactions between buprenorphine and antiretrovirals II: Protease inhibitors, nelfinavir, lopinavir/ritonavir, or ritonavir. Clin Infect Dis 2006, 43(Suppl 4):S235-S246. Unlike for methadone, buprenorphine is not associated with opiate withdrawal when coadministered with standard clinical doses of these PIs.
40. Bruce RD, Altice FL, Moody DE, et al.: Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ ritonavir in HIV-negative subjects chronically receiving buprenorphine/ naloxone. Drug Alcohol Depend 2009, 105:234-239.Ten HIV-negative patients on buprenorphine maintenance received tipranavir/naloxone for 7 days or more (until steady state was achieved). Buprenorphine AUC did not changesignificantly. However, tipranavir AUC decreased 19% compared to historical control subjects receiving tipranavir/ritonavir alone.
41. McCance-Katz EF, Moody DE, Morse GD, et al.: Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug Alcohol Depend 2007, 91:269-278. Ten HIV-negative patients on buprenorphine maintenance received atazanavir/ ritonavir for 5 days. Atazanavir/ritonavir increased concentrations of buprenorphine, norbuprenorphine, and their glucuronides, and three patients reported increased sedation.
42. Bruce RD, Altice FL: Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir. AIDS 2006, 20:783-784.
43. Rainey PM, Friedland G, McCance-Katz EF, et al.: Interaction of methadone with didanosine (ddI) and stavudine (d4T). J Acquir Immune Defic Syn Hum Retrovirol 2000, 24:241-248.
44. Friedland G, Rainey P, Jatlow P, et al.: Pharmacokinetics of didanosine from encapsulated enteric coated bead formulation vs.chewable tablet formulation in patients on chronic methadone therapy. Paper Presented at the 14th International AIDS Conference.Barcelona, Spain; July 2002.
45. Baker J, Rainey PM, Moody DE, et al.: Interaction of buprenorphine with the nucleoside reverse transcriptase inhibitors: didanosine, tenofovir, and lamivudine. Am J Addict 2010, 19:17-29.
46. McCance-Katz EF, Jatlow P, Rainey P, Friedland G: Methadone effects on zidovudine (AZT) disposition (ACTG 262).J Acquir Immune Defic Syn Hum Retrovirol 1998, 18:435-443.Showed evidence for increased zidovudine concentrations in methadone-maintained patients that could mimic opiate withdrawal. Alterations may be related to the effect of methadone on zidovudine glucuronidation.
47. McCance-Katz EF, Rainey PM, Friedland G, et al.: Effect of opioid dependence pharmacotherapies on zidovudine disposition.Am J Addict 2001, 10:296-307. Lack of effect of l-acetyl-methadol, buprenorphine, or naltrexone on zidovudine disposition showed that patients could be matched to treatments for opioid dependence or HIV disease based on reducing likelihood of drug-drug interactions.
48. McCance-Katz EF, Rainey P, Smith P, et al.: Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and delavirdine. Am J Addict 2006, 15:23-34.
49. Darunavir (Prezista) Product Label. http://www.fda.gov/cder/foi/label/ 2008/021976s009lbl.pdf Accessed June 3, 2009.
50. Nelfinavir (Viracept) Product Label. http://www.fda.gov/cder/foi/label/ 2008/020778s029,020779s050,021503s011lbl.pdf Accessed June 3, 2009.